RESULTS OF FIRST-LINE OSIMERTINIB TREATMENT IN PATIENTS WITH EGFR-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER AT HANOI ONCOLOGY HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the results of Osimertinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer at Hanoi Oncology Hospital. Subjects and methods: A cross-sectional descriptive study was designed combined with a retrospective review of 46 patients diagnosed by histopathology as stage IIIB, IIIC, IV non-small cell lung cancer, with metastatic recurrence according to AJCC 8 version at Hanoi Oncology Hospital from March 2024 to June 2024. Results: The mean response time was 2.4 ± 1 week. The complete response rate was calculated as 4.3%; 82.6% of patients had a partial response, 8.7% had stable disease, and 4.3% of patients showed disease progression. The mean progression-free survival time was 17.2 ± 1.45 months. The main toxicities found were skin rash, dry skin, and diarrhea, which manifested at grade 1.2. There were no cases requiring permanent discontinuation of treatment due to the drug. Conclusion: Osimertinib is one of the preferred options for patients with EGFR-mutant advanced non-small cell lung cancer, which help to improve symptoms, prolong disease-free survival, and is safe with low toxicity.
Article Details
Keywords
lung cancer, non-small cell lung cancer, EGFR mutation, Osimertinib
References

2. Wu Yi-Long, Tsuboi Masahiro, He Jie et al. (2020), Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer, New England Journal of Medicine, 383(18), 1711-1723.

3. Bộ Y tế (2020), Quyết định 1514/QĐ-BYT ngày 1/4/2020 về ban hành tài liệu chuyên môn "Hướng dẫn chẩn đoán và điều trị một số bệnh ung bướu", chủ biên.

4. Nguyễn Đình Đức, Đỗ Hùng Kiên, Trịnh Lê Huy (2023), Kết quả điều trị bước một ung thư phổi không tế bào nhỏ di căn não có đột biến EGFR bằng Osimertinib, Tạp chí Y học Việt Nam, 1(532), 56-60.

5. Đặng Văn Khiêm, Phương Ngọc Anh, Cấn Xuân Hạnh và các cộng sự. (2022), Đánh giá kết quả điều trị bước một ung thư phổi giai đoạn IV bằng Osimertinib bước 1 tại bệnh viện Phổi Trung ương, Tạp chí Y học Việt Nam, số chuyên đè(520), 133-140.

6. Jänne P, Planchard D, Cheng et al. (2023), Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2), 2023 World Conference on Lung Cancer, Abstract PL03(13), Presented September 11.

7. Lorenzi M, Ferro A, Cecere F vet al. (2022), First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study, Oncologist, 27(2), 87-e115.

8. Watanabe K, Yoh K, Hosomi Y et al. (2022), Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study, BMJ Open, 12(1), e046451.
